-
1.发明公开公开(公告)号：US20240343796A1
公开(公告)日：2024-10-17
申请号：US18528157
申请日：2023-12-04
Applicant: Janssen Biotech, Inc.
Inventor： Ricardo Attar , Francois Gaudet , Mark Tornetta , Alexey Teplyakov , Mark Mendonca , Suzanne Edavettal , Kodandaram Pillarisetti , Nathan Majewski , Yingzhe Li , Leopoldo L. Luistro, III , Diana Chin
CPC classification number: C07K16/28 , A61K39/0011 , C07K16/2809 , A61K2039/505 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.
-
2.发明授权公开(公告)号：US10301392B2
公开(公告)日：2019-05-28
申请号：US15596609
申请日：2017-05-16
Applicant: Janssen Biotech, Inc.
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
-
公开(公告)号：US09932404B2
公开(公告)日：2018-04-03
申请号：US15345860
申请日：2016-11-08
Applicant: Janssen Biotech, Inc.
Inventor： Mark Cunningham , Yiqing Feng , Katharine Heeringa , Jinquan Luo , Robert Rauchenberger , Mark Rutz , Lani San Mateo , Robert Sarisky , Raymond Sweet , Fang Teng , Alexey Teplyakov , Sheng-Jiun Wu
IPC: A61K39/395 , C07K16/28 , C07H21/04 , C12N15/117 , C07K14/705 , C12N5/10 , C12N5/12 , C12N15/63 , A61K39/00
CPC classification number: C07K16/2896 , A61K39/39533 , A61K39/3955 , A61K2039/505 , C07H21/04 , C07K14/705 , C07K16/18 , C07K16/28 , C07K16/2863 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C12N5/10 , C12N5/12 , C12N15/117 , C12N15/63 , C12N2310/17 , A61K39/00 , A61K2300/00
Abstract: Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.
-
公开(公告)号：US20170037136A1
公开(公告)日：2017-02-09
申请号：US15228582
申请日：2016-08-04
Applicant: Janssen Biotech, Inc.
Inventor： Johan Fransson , Galina Obmolova , Anish Suri , Fang Teng , Alexey Teplyakov , Hong Zhou , Jocelyn Leu
IPC: C07K16/28 , G01N33/68 , C07K16/42 , A61K39/395 , A61K45/06
Abstract: The present invention relates to antagonistic antibodies specifically binding CD154, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
Abstract translation: 本发明涉及特异性结合CD154的拮抗性抗体，编码抗体或片段的多核苷酸，以及制备和使用上述物质的方法。
-
公开(公告)号：US20140234304A1
公开(公告)日：2014-08-21
申请号：US14230128
申请日：2014-03-31
Applicant: Janssen Biotech, Inc.
Inventor： Juan Carlos ALMAGRO , Glenn Mark Anderson , Ellen Chi , Christian Martinez , Gopalan Raghunathan , Ronald Swanson , Alexey Teplyakov , Kam-Fai Tse , Sheng-Jiun Wu , Hong Mimi Zhou
IPC: C07K16/40
CPC classification number: C07K16/40 , A61K2039/505 , C07K16/28 , C07K16/36 , C07K16/464 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/524 , C07K2317/55 , C07K2317/565 , C07K2317/72 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
Abstract translation: 本发明涉及能够预防组织因子（凝血因子F3）信号传导但不干扰因子VII结合或FX与组织因子结合并且不延长凝血时间的抗体的人源化形式。 本发明的抗体可用于治疗相关细胞表达组织因子和组织因子信号传导的病症，例如肿瘤进展。
-
Patent Agency Ranking
公开(公告)号：US20240141055A1
公开(公告)日：2024-05-02
申请号：US18216074
申请日：2023-06-29
Applicant: Janssen Biotech, Inc
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
IPC: C07K16/28
CPC classification number: C07K16/2878 , C07K16/2896 , A61K2039/505
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
-
公开(公告)号：US10562948B2
公开(公告)日：2020-02-18
申请号：US15616216
申请日：2017-06-07
Applicant: Janssen Biotech, Inc.
Inventor： Thomas Rutkoski , Alexey Teplyakov , Nicole Wunderler
IPC: C07K14/535 , A61K38/19 , A61K45/06
Abstract: GM-CSF variants, polynucleotides encoding them, and methods of making and using the foregoing are useful in treatment of immune-related disorders, such as inflammatory bowel disease (IBD).
-
公开(公告)号：US20190248910A1
公开(公告)日：2019-08-15
申请号：US16382645
申请日：2019-04-12
Applicant: Janssen Biotech, Inc
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
IPC: C07K16/28
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
-
公开(公告)号：US20150299330A1
公开(公告)日：2015-10-22
申请号：US14790144
申请日：2015-07-02
Applicant: JANSSEN BIOTECH, INC.
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
IPC: C07K16/28
CPC classification number: C07K16/2878 , A61K2039/505 , C07K16/2896 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
Abstract translation: 对人CD27免疫特异性的人抗体能够阻断CD27与其配体CD70结合并中和CD27的生物活性，包括但不限于CD27细胞内信号传导，T细胞增殖和活化，B细胞增殖和分化，浆细胞形成和缓解 的抗体反应，通过CD70刺激肿瘤细胞，以及从T和B细胞产生可溶性介质。 该抗体可用于诊断或治疗CD27活动相关疾病和病症。
-
公开(公告)号：US20130243795A1
公开(公告)日：2013-09-19
申请号：US13835518
申请日：2013-03-15
Applicant: JANSSEN BIOTECH, INC.
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
IPC: C07K16/28
CPC classification number: C07K16/2878 , A61K2039/505 , C07K16/2896 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
Abstract translation: 对人CD27免疫特异性的人抗体能够阻断CD27与其配体CD70结合并中和CD27的生物活性，包括但不限于CD27细胞内信号传导，T细胞增殖和活化，B细胞增殖和分化，浆细胞形成和缓解 的抗体反应，通过CD70刺激肿瘤细胞，以及从T和B细胞产生可溶性介质。 该抗体可用于诊断或治疗CD27活动相关疾病和病症。
-
-
-
-
-
-
-
-
-
Search Results
39
records
(took 0.029 seconds)
